Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Hepregen Announces Appointment of Dr. Michael Holsapple

Published: Wednesday, August 07, 2013
Last Updated: Wednesday, August 07, 2013
Bookmark and Share
Appointment adds respected leader in toxicology to Hepregen’s senior management team, reflecting ongoing commitment of Hepregen’s strategic investor, Battelle Memorial Institute.

Hepregen Corporation has announced the appointment of Dr. Michael P. Holsapple as Vice President of Toxicology Product Development.

This appointment of Dr. Holsapple, who will also retain his position at Battelle Memorial Institute (“Battelle”), was accomplished as a part of an investment and commercial development strategy co-elaborated by senior management at Hepregen and Battelle.

Following a successful 13-year academic career, Dr. Holsapple was leader of the Immunotoxicology and Respiratory Toxicology groups at Dow Chemical for eight years, after which, from 2002 to 2011, he served as the Executive Director of the Health and Environmental Sciences Institute (HESI), the global branch of the International Life Sciences Institute (ILSI) in Washington, DC.

He joined Battelle in 2011 as a Senior Leader Research in systems toxicology. Dr. Holsapple received the Society of Toxicology (SOT) Achievement Award in 1992.

In recognition of his contributions to immunotoxicology, he received the Vos Award: Career Achievement in Immunotoxicology in 2009.

Dr. Holsapple has served on Council for the SOT, and on Council for the American College of Toxicology (ACT). He was elected a ‘fellow’ in the Academy of Toxicological Sciences (ATS) in 2006, and a member of the Board of Trustees of the ATS in 2013. He is also a past President of the SOT.

Dr. Holsapple stated, “Hepregen has become the leader in next generation in vitro micro-liver products. Joining the Company’s outstanding team of scientists and commercially experienced senior managers is without a doubt an exceptional opportunity to participate in development of products that can transform the pharmaceutical, cosmetics and chemical industries.”

“Mike’s incredibly extensive scientific and organizational background in the field of toxicology provides Hepregen with an unmatched resource,” stated Dr. Vincent Zurawski, Hepregen’s chief executive officer, adding, “He brings a wealth of knowledge and experience to our emerging global enterprise.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement
Agreement provides for European sales of Hepregen's HepatoPac® and HepatoMune™ proprietary products by SOLVO and provision of services using these products.
Wednesday, June 24, 2015
QTS and Hepregen Execute Co-Development and Co-Marketing Agreement
Agreement provides for development, manufacture and sale of HepatoPac® B-CLEAR® co-labeled proprietary products for liver transporter analysis.
Tuesday, November 04, 2014
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Nanoparticles Target, Transform Fat Tissue
Nanoparticles designed to target white fat and convert it to calorie-burning brown fat slowed weight gain in obese mice without affecting food intake. This proof-of-concept work could lead to new therapies to treat obesity.
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!